Literature DB >> 29610507

Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report.

Kelly C Cushing1, Mari Mino-Kenudson2, John Garber1, Paul Lochhead3, Hamed Khalili1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29610507     DOI： 10.1038/ajg.2018.7

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

Review 1.  Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis.

Authors:  Jinlu Tong; Qing Zheng; Qinq Zheng; Chenpeng Zhang; Ryan Lo; Jun Shen; Zhihua Ran
Journal:  Am J Gastroenterol       Date:  2015-01-27       Impact factor: 10.864

Review 2.  Diagnosis and Management of Microscopic Colitis.

Authors:  Darrell S Pardi
Journal:  Am J Gastroenterol       Date:  2016-11-29       Impact factor: 10.864

3.  Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Authors:  Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

4.  Vedolizumab as induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

Review 5.  Microscopic Colitis: What Do We Know About Pathogenesis?

Authors:  Laura Francesca Pisani; Gian Eugenio Tontini; Maurizio Vecchi; Luca Pastorelli
Journal:  Inflamm Bowel Dis       Date:  2016-02       Impact factor: 5.325
  5 in total
  4 in total

Review 1.  Diagnosis and Management of Microscopic Colitis in Pediatric Patients.

Authors:  Salina Khushal; Maria Oliva-Hemker
Journal:  Paediatr Drugs       Date:  2022-05-02       Impact factor: 3.022

2.  Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis.

Authors:  Laura Besendorf; Tanja M Müller; Carol-Immanuel Geppert; Ines Schneider; Laura Mühl; Imke Atreya; Francesco Vitali; Raja Atreya; Markus F Neurath; Sebastian Zundler
Journal:  Therap Adv Gastroenterol       Date:  2022-06-28       Impact factor: 4.802

3.  European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations.

Authors:  Stephan Miehlke; Danila Guagnozzi; Yamile Zabana; Gian E Tontini; Anne-Marie Kanstrup Fiehn; Signe Wildt; Johan Bohr; Ole Bonderup; Gerd Bouma; Mauro D'Amato; Peter J Heiberg Engel; Fernando Fernandez-Banares; Gilles Macaigne; Henrik Hjortswang; Elisabeth Hultgren-Hörnquist; Anastasios Koulaouzidis; Jouzas Kupcinskas; Stefania Landolfi; Giovanni Latella; Alfredo Lucendo; Ivan Lyutakov; Ahmed Madisch; Fernando Magro; Wojciech Marlicz; Emese Mihaly; Lars K Munck; Ann-Elisabeth Ostvik; Árpád V Patai; Plamen Penchev; Karolina Skonieczna-Żydecka; Bas Verhaegh; Andreas Münch
Journal:  United European Gastroenterol J       Date:  2021-02-22       Impact factor: 4.623

4.  Safe and Successful Treatment of Acute Cellular Rejection of an Intestine and Abdominal Wall Transplant With Vedolizumab.

Authors:  Guido Trentadue; Gursah Kats-Ugurlu; Tjasso Blokzijl; Gilles Fh Diercks; Jan Willem Haveman; Klaas Nico Faber; Gerard Dijkstra
Journal:  Transplant Direct       Date:  2020-01-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.